CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development market conditions, as trial activity has been impacted by cautious spending from biopharma customers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback